BioCentury
ARTICLE | Finance

Amicable for Amicus

Amicus, GSK revise Fabry's deal, biotech gets U.S. rights to migalastat

July 23, 2012 7:00 AM UTC

Orphan disease play Amicus Therapeutics Inc. (NASDAQ:FOLD) gave up potential milestone payments from partner GlaxoSmithKline plc last week and assumed more development costs in exchange for U.S. commercial rights in their Fabry's disease deal.

The biotech ceded $166.5 million in milestones and assumed 40% of R&D expenses, up from 25%...